Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries

Linde, Louise ; Ørnbjerg, Lykke M. ; Georgiadis, Stylianos ; Rasmussen, Simon H. ; Lindström, Ulf ; Askling, Johan ; Michelsen, Brigitte ; Di Giuseppe, Daniela ; Wallman, Johan K. LU and Gudbjornsson, Bjorn , et al. (2024) In Rheumatology (United Kingdom) 63(3). p.751-764
Abstract

Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of... (More)

Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6954, n=5275 and n=13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
DAPSA28, drug retention, first TNF-inhibitor, predictors, PsA, real-world evidence
in
Rheumatology (United Kingdom)
volume
63
issue
3
pages
14 pages
publisher
Oxford University Press
external identifiers
  • pmid:37314967
  • scopus:85186323294
ISSN
1462-0324
DOI
10.1093/rheumatology/kead284
language
English
LU publication?
yes
id
fbf3b100-aed3-4594-9218-1d6a0fcff35e
date added to LUP
2024-03-15 14:09:04
date last changed
2024-04-26 11:30:03
@article{fbf3b100-aed3-4594-9218-1d6a0fcff35e,
  abstract     = {{<p>Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6954, n=5275 and n=13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (&lt;2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of &gt;10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.</p>}},
  author       = {{Linde, Louise and Ørnbjerg, Lykke M. and Georgiadis, Stylianos and Rasmussen, Simon H. and Lindström, Ulf and Askling, Johan and Michelsen, Brigitte and Di Giuseppe, Daniela and Wallman, Johan K. and Gudbjornsson, Bjorn and Love, Thorvardur Jon and Nordström, Dan C. and Yli-Kerttula, Timo and Nekvindová, Lucie and Vencovský, Jiří and Iannone, Florenzo and Cauli, Alberto and Loft, Anne Gitte and Glintborg, Bente and Laas, Karin and Rotar, Ziga and Tomšič, Matija and MacFarlane, Gary J. and Möller, Burkhard and Van De Sande, Marleen and Codreanu, Catalin and Nissen, Michael J. and Birlik, Merih and Erten, Sukran and Santos, Maria J. and Vieira-Sousa, Elsa and Hetland, Merete L. and Østergaard, Mikkel}},
  issn         = {{1462-0324}},
  keywords     = {{DAPSA28; drug retention; first TNF-inhibitor; predictors; PsA; real-world evidence}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{751--764}},
  publisher    = {{Oxford University Press}},
  series       = {{Rheumatology (United Kingdom)}},
  title        = {{Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries}},
  url          = {{http://dx.doi.org/10.1093/rheumatology/kead284}},
  doi          = {{10.1093/rheumatology/kead284}},
  volume       = {{63}},
  year         = {{2024}},
}